22:44 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Epilepsy In vitro, mouse and rat studies identified a benzenesulfonamide-based CAII inhibitor that could help treat epilepsy. Chemical synthesis of benzenesulfonamide analogs and in vitro activity assays yielded a compound that inhibited CAII with...
07:00 , May 23, 2016 |  BioCentury  |  Strategy

Two heads are better

With Gleevec imatinib off patent, flagging ophthalmics sales and at least one slower than expected launch, Novartis AG is consolidating operations at the top to cut costs, while also splitting its R&D into two buckets:...
07:00 , Apr 2, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carbonic anhydrase II (CAII); nitric oxide (NO)

Ophthalmic disease INDICATION: Glaucoma In vitro and animal studies suggest an NO-donating analog of the CAII inhibitor brinzolamide could help treat glaucoma by reducing intraocular pressure (IOP). Brinzolamide reduces aqueous humor production, whereas NO induces aqueous humor...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

Novartis’ Alcon Inc. ophthalmic unit said the European Commission approved an MAA for Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension for whom monotherapy provides an...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

EMA's CHMP recommended approval of an MAA from Novartis' Alcon Inc. ophthalmic unit for Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

Novartis' Alcon Inc. ophthalmic unit said FDA approved Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The product is a fixed combination of 1% brinzolamide, a...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Brinzolamide/brimonidine tartrate regulatory update

Novartis disclosed in its 2Q12 earnings that its Alcon Inc. ophthalmic unit filed a regulatory application in the U.S. for brinzolamide/brimonidine tartrate to treat intraocular pressure in patients with glaucoma. The product is a...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

Azarga brinzolamide/timolol regulatory update

EMEA approved an MAA from Alcon for Azarga brinzolamid/timolol to treat elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension in adults for whom monotherapy is insufficient. The brinzolamid/timolol eye drop combines 10...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

Azarga brinzolamide/timolol regulatory update

EMEA's CHMP recommended approval of an MAA from Alcon for Azarga brinzolamid/timolol to reduce intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. Azarga is...
07:00 , Apr 28, 2008 |  BC Week In Review  |  Clinical News

Azopt brinzolamide regulatory update

EMEA's CHMP issued a positive opinion to extend the indication of Azopt brinzolamide ophthalmic solution to include adjunct use with prostaglandin analogs to decrease elevated intraocular pressure (IOP) in ocular hypertension and open-angle glaucoma. Alcon...